Serum potassium in the PARADIGM-HF trial.


Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
11 2020
Historique:
received: 31 05 2020
revised: 28 07 2020
accepted: 07 08 2020
pubmed: 19 8 2020
medline: 10 6 2021
entrez: 19 8 2020
Statut: ppublish

Résumé

The associations between potassium level and outcomes, the effect of sacubitril-valsartan on potassium level, and whether potassium level modified the effect of sacubitril-valsartan in patients with heart failure and a reduced ejection fraction were studied in PARADIGM-HF. Several outcomes, including cardiovascular death, sudden death, pump failure death, non-cardiovascular death and heart failure hospitalization, were examined. A total of 8399 patients were randomized to either enalapril or sacubitril-valsartan. Potassium level at randomization and follow-up was examined as a continuous and categorical variable (≤3.5, 3.6-4.0, 4.1-4.9, 5.0-5.4 and ≥5.5 mmol/L) in various statistical models. Hyperkalaemia was defined as K Although both higher and lower potassium levels were independent predictors of cardiovascular death, potassium abnormalities may mainly be markers rather than mediators of risk for death.

Identifiants

pubmed: 32809261
doi: 10.1002/ejhf.1987
pmc: PMC7756204
doi:

Substances chimiques

Aminobutyrates 0
Angiotensin Receptor Antagonists 0
Angiotensin-Converting Enzyme Inhibitors 0
Biphenyl Compounds 0
Drug Combinations 0
Enalapril 69PN84IO1A
Valsartan 80M03YXJ7I
Potassium RWP5GA015D
sacubitril and valsartan sodium hydrate drug combination WB8FT61183

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2056-2064

Subventions

Organisme : British Heart Foundation
ID : RE/18/6/34217
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Eur J Heart Fail. 2020 Aug;22(8):1378-1389
pubmed: 32243669
Prog Cardiovasc Dis. 1966 Mar;8(5):387-418
pubmed: 5324828
J Am Coll Cardiol. 2004 Jan 21;43(2):155-61
pubmed: 14736430
JAMA. 2019 Feb 12;321(6):602-603
pubmed: 30676631
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Angiology. 2018 Sep;69(8):709-717
pubmed: 29117714
Am J Nephrol. 2017;46(3):213-221
pubmed: 28866674
Eur J Clin Pharmacol. 1988;35(4):409-12
pubmed: 2848707
Eur Heart J. 2017 Oct 7;38(38):2890-2896
pubmed: 29019614
N Engl J Med. 2004 Aug 5;351(6):585-92
pubmed: 15295051
Eur Heart J. 2016 Nov 01;37(41):3167-3174
pubmed: 27354044
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Clin Sci (Lond). 1986 May;70(5):507-12
pubmed: 2938872
JAMA Cardiol. 2017 Jan 1;2(1):79-85
pubmed: 27842179
JAMA. 2012 Jan 11;307(2):157-64
pubmed: 22235086
Eur Heart J. 2017 Jan 7;38(2):104-112
pubmed: 28158516
Nephron Clin Pract. 2012;120(1):c8-16
pubmed: 22156587
Eur Heart J. 2018 May 1;39(17):1535-1542
pubmed: 29554312
Eur Heart J. 2017 Oct 7;38(38):2897-2899
pubmed: 29019617
Eur J Heart Fail. 2017 Jun;19(6):792-799
pubmed: 27868385
J Am Soc Hypertens. 2017 Dec;11(12):783-800
pubmed: 29030153
J Am Coll Cardiol. 2016 Sep 27;68(13):1476-1488
pubmed: 27216111
Eur J Heart Fail. 2020 Aug;22(8):1390-1398
pubmed: 32078214
Lancet. 2020 Jul 11;396(10244):121-128
pubmed: 32446323
JACC Heart Fail. 2019 Jan;7(1):65-76
pubmed: 30553905
Circulation. 2018 Mar 27;137(13):1320-1330
pubmed: 29025765
Eur Heart J Suppl. 2019 Feb;21(Suppl A):A55-A60
pubmed: 30837806
Circ Arrhythm Electrophysiol. 2017 Mar;10(3):
pubmed: 28314851
J Am Coll Cardiol. 2020 Jun 9;75(22):2836-2850
pubmed: 32498812

Auteurs

João Pedro Ferreira (JP)

National Institute of Health and Medical Research, Centre for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

Ulrik M Mogensen (UM)

Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Pardeep S Jhund (PS)

British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

Akshay S Desai (AS)

Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.

Jean-Lucien Rouleau (JL)

Montreal Heart Institute, Montreal, QC, Canada.

Michael R Zile (MR)

Medical University of South Carolina and Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA.

Patrick Rossignol (P)

National Institute of Health and Medical Research, Centre for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.

Faiez Zannad (F)

National Institute of Health and Medical Research, Centre for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.

Milton Packer (M)

Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.

Scott D Solomon (SD)

Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.

John J V McMurray (JJV)

British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH